|
IFOND research | LHON treatment prospects | Mitochondrial Genome Editing | COVID-19 and LHON | LHON talks | Pay it forward | Mitochondrial Regulation | Avoid BAK eye drop preservative, etc. | We experiment with cigarette smoke so you need not. | Viral vector trials | EPI-743 LHON trials | Idebenone LHON trials
Digests: NEI News | Mitochondrial Disease News LHON | ARVO Journals LHON | PubMed LHON | Europe PMC LHON | MRC-MBU newsCigarette smoke is strongly associated with affected LHON cases
This IFOND funded study [full text free], part of the ongoing LHON - Brazil Project, for the first time clarifies the association and mechanism of toxic tobacco smoke on loss of sight in those affected by Leber Hereditary Optic Neuropathy (LHON): L. Giordano, et al. Cigarette toxicity triggers Leber's hereditary optic neuropathy by affecting mtDNA copy number, oxidative phosphorylation and ROS detoxification pathways. Cell Death Dis. 2015 Dec; 6(12): e2021. Some of their research colleagues have noted that, rather strikingly, the clinical penetrance of the LHON mtDNA mutations was 93% in the males who smoked compared to 50% in the literature. Further research may find further, likely genetic, factors predicting those LHON carriers at higher risk of becoming affected. This is but one of many IFOND studies, arising from its sponsorship of the LHON Brazil Project, devoted to understanding and therapy of LHON.
The International Foundation for
Optic Nerve Disease
P. O. Box 777, Cornwall NY 12518, USA.
Phone/Fax: (845)5348606
Email: ifond@aol.com
Web site:
http://www.ifond.org/
IFOND is registered service mark of
The International Foundation for Optic Nerve Disease, est. October 1995.
Copyright 1999-2024, International Foundation for
Optic Nerve Disease.
The information contained on this website should not be considered medical guidance or professional advice. IFOND is not responsible for errors or omissions in information provided on this site or actions resulting from its use. IFOND does not publish all information from all available sources on optic nerve disease. IFOND is not responsible for the validity of the studies or reviews nor is it an advocate of studies or reviews mentioned on or linked from the IFOND web site. IFOND does not endorse or recommend participation in any particular clinical trial or treatment protocol which may be mentioned on this site. Direct any questions concerning your personal health to your appropriate health care professional.